A federal judge on Monday struck down the Trump administration's $100,000 fee on new H-1B visas. The administration announced the fee as a way of preventing foreign workers from taking American jobs. (Image credit: Wilfredo Lee)
A federal judge on Monday struck down the Trump administration's $100,000 fee on new H-1B visas. The administration announced the fee as a way of preventing foreign workers from taking American jobs. (Image credit: Wilfredo Lee)
For millions of people, posting online is no longer just a hobby. It's a business. More than 200 million people considered themselves creators as of 2025. In the U.S. alone, 27 million creators make income through content, according to Salesforce data. And the money behind this work is also growing ...
For millions of people, posting online is no longer just a hobby. It's a business. More than 200 million people considered themselves creators as of 2025. In the U.S. alone, 27 million creators make income through content, according to Salesforce data. And the money behind this work is also growing ...
GLP Pte. told some bondholders during meetings in recent days that it aims to sell around $2 billion of assets this year, according to people familiar with the matter, as the logistics operator prepares for an initial public offering. The push to shed assets includes talks with Ares Management Corp. to sell some international data centers, the people said, asking not to be identified as the matter...
GLP Pte. told some bondholders during meetings in recent days that it aims to sell around $2 billion of assets this year, according to people familiar with the matter, as the logistics operator prepares for an initial public offering. The push to shed assets includes talks with Ares Management Corp. to sell some international data centers, the people said, asking not to be identified as the matter is private. GLP didn’t elaborate on other asset disposal plans, they added. The moves are part of GLP’s broader efforts to strengthen its finances and reassure investors over liquidity ahead of an IPO planned for this year. The company reported last month that it swung to a profit in 2025, partly on the strength of its data center business. The earnings report was closely watched as investors sought a clearer view of the company’s finances after a drop in its dollar bond prices. In a separate deal last year, GLP agreed to sell GCP International to Ares for up to $5.2 billion. The latest talks are part of that agreement, and can help GLP qualify for an extra payout, the people said. That’s because under the terms of the GCP International sale, GLP can qualify for a payment of up to $1.5 billion if it meets certain performance targets, according to a notice posted on the company’s website. GLP still has about $5 billion of assets outside of China after the sale of GCP International, including data centers and logistics operations, the people said. GLP has come under pressure in the bond market after credit news provider Octus reported in March that China’s financial regulator had informally advised insurers to limit transactions with GLP’s mainland logistics and asset‑management units. GLP disputed the report at that time, saying that it hadn’t received any such notification from any regulatory authority and Chinese insurers remain actively engaged in both existing and prospective commitments. Its dollar notes due 2028 are currently trading at around 88 cents on the dollar, ...
utah778/iStock via Getty Images Market Overview Following a strong 2025 for credit markets broadly, mounting headwinds in early 2026 prompted a sharp increase in volatility and a repricing of risk. We've written previously about the importance of prudence in today's market environment of tight spreads, yield compression and heightened idiosyncratic risk, and we believe the swift repricing of credi...
utah778/iStock via Getty Images Market Overview Following a strong 2025 for credit markets broadly, mounting headwinds in early 2026 prompted a sharp increase in volatility and a repricing of risk. We've written previously about the importance of prudence in today's market environment of tight spreads, yield compression and heightened idiosyncratic risk, and we believe the swift repricing of credit markets in the first quarter underscores our view that caution is the new conviction. The Bloomberg US Aggregate Bond Index was flat for the quarter, while the Bloomberg Global Aggregate Index declined 1.1% and the S&P UBS Leveraged Loan Index fell 0.5%. Equities fared even worse, with the S&P 500 Index down 4.3%. ¹ Credit Markets Swiftly Reprice Risk US broadly syndicated loan activity cooled in the first quarter; total primary market activity amounted to only $241 billion, 32% slower than 2025's pace. Overall activity remained focused on opportunistic loan repricings and refinancings, though volumes in both areas were well off year-ago levels. While new-money issuance related to mergers and acquisitions (M&A) picked up relative to last year, its concentration in a handful of very large transactions combined with flagging private equity dealmaking suggest headwinds to loan issuance may persist. In the secondary market, the weighted average bid of leveraged loans continued to decline, though ended the quarter above early-March lows; notably, the price change was far less severe when excluding the software sector. ² New issuance of collateralized loan obligations (CLOs), the primary driver of demand for broadly syndicated loans, eased in February and March after a robust start to the year. That said, CLO issuance during the quarter was modestly higher on a year-over-year basis and represented the second-strongest first quarter mark on record. ³ Given CLOs' track record of very low impairments relative to like-rated corporates bonds, institutional buyers—including banks, in...
IDEAYA Biosciences ( IDYA ) has announced the pricing of an underwritten public offering to raise aggregate gross proceeds of approximately $300.0M, by selling 5.56M shares of common stock at a public offering price of $27.00 per share. The company is also issuing pre-funded warrants to purchase an additional 5.56M shares of common stock, priced at $26.9999 per warrant with a nominal exercise pric...
IDEAYA Biosciences ( IDYA ) has announced the pricing of an underwritten public offering to raise aggregate gross proceeds of approximately $300.0M, by selling 5.56M shares of common stock at a public offering price of $27.00 per share. The company is also issuing pre-funded warrants to purchase an additional 5.56M shares of common stock, priced at $26.9999 per warrant with a nominal exercise price of $0.0001 per share. IDEAYA has granted the underwriters a 30-day option to purchase up to an additional 1.67M shares of common stock at the public offering price. The transaction is expected to close on or about June 10, 2026, subject to customary closing conditions. More on IDEAYA Biosciences IDEAYA Biosciences, Inc. (IDYA) Presents at Bank of America Global Healthcare Conference 2026 Transcript IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal Melanoma - Slideshow Ideaya Biosciences: Stock Buoyant On Good mUM Data - But Approval Not A Formality IDEAYA files shelf offering to raise up to $300M IDEAYA to work with Roche on combo pancreatic cancer treatment